Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New York Times Examines Program To Help Orphans Survive 'Fragile Days Of Infancy'
The New York Times examines a program being offered at an orphanage in Tanzania that provides emotional and physical support for newborns and young children who are at a high risk of death after losing their mothers in infancy. "Africa is full of at least 50 million orphans, the legacy of AIDS and other diseases, war and high rates of death in pregnancy and childbirth," the newspaper writes. "With the numbers increasing every day, Africans are struggling to care for them, often in ways that differ strikingly from the traditional concept of an orphanage in the developed world."
generic viagra online
Doctors Talk Frankly About What Encourages And Impedes Early Diagnosis Of Alzheimer's
A doctor"s positive attitude to Alzheimer"s diagnosis and their trusting, personal relationships with local dementia support service providers are powerful enablers for early diagnosis of Alzheimer"s, according to new research reported at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna.
News of the day
VYVANSE CII Provided Significant Efficacy At 14 Hours After Administration In Adults With ADHD In An Adult Simulated Workplace Environment
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD). VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented today at the 49th annual New Clinical Drug Evaluation Unit meeting in Hollywood, FL. VYVANSE is currently approved by the US Food and Drug Administration (FDA) for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD.
Public Health

Genzyme Receives Positive Opinion For European Approval Of Mozobil

Genzyme Corporation (Nasdaq: GENZ) announced that the European Medicines Agency"s Committee for Human Medicinal Products (CHMP) has adopted a positive opinion on the marketing authorization application for Mozobil ® (plerixafor injection). The committee"s opinion will be forwarded to the European Commission, which will make a final decision on the authorization. The Commission has 66 calendar days to act on the CHMP"s opinion. In the EU, Mozobil would be indicated in combination with granulocyte-colony stimulating factor to enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilize poorly. "For many patients with lymphoma or multiple myeloma, moving on to a transplant is their only hope for remission or a cure," said Gerhard Ehninger, Professor of Medicine at Dresden Technology University and Chairman of the German Society of Hematology and Oncology. "Mozobil is an innovative treatment that, upon approval, can give these patients an opportunity to achieve a timely and successful transplant." In order for a blood stem cell transplant to take place, a minimum number of such cells must be collected. For many patients, this process can take three or four hours over multiple days to complete. Even then, some patients are not able to mobilize enough cells, and a transplant is not possible. Mozobil has been shown in clinical studies to rapidly and effectively increase the number of stem cells in circulation in the blood in patients with lymphoma and multiple myeloma. In Europe, patients have received Mozobil through compassionate use and named patient programs. In addition to its benefits for patients, Mozobil offers potential economic benefits to transplant centers by decreasing the number of days needed to collect stem cells, a procedure known as apheresis. This can provide transplant centers with a more predictable and efficient use of their apheresis centers. Mozobil may also reduce the number of patients who require a second mobilization procedure because of a failure to mobilize a sufficient number of cells. Genzyme received FDA approval of Mozobil in December 2008. The company plans to submit additional applications in up to 60 countries. About Mozobil Mozobil, a novel small molecule CXCR4 chemokine receptor antagonist, has been shown in multiple earlier studies to rapidly and effectively increase the number of stem cells in circulation in the blood in patients with non-Hodgkin"s lymphoma and multiple myeloma. Once circulating in the blood, stem cells can be collected for use in an autologous stem cell transplant. Genzyme Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009